LATTICE BIOLOGICS LTD

LATTICE BIOLOGICS LTD

OOTC:LBLTF
0.00
USD
0.00
(0.00%)
LATTICE BIOLOGICS LTD
OTC:LBLTF
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Lattice Biologics Ltd. (LBLTF) is a biotechnology company that develops, manufactures, and markets biologic allograft products for cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. The company offers acellular demineralized bone scaffolds for orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; acellular dermal matrices that promote cellular ingrowth, tissue vascularization, and regeneration; amniotic fluid-based products including AmnioBoost and AmnioBlast; soft tissue allografts; dental allografts; membrane and barrier allografts; and demineralized bone matrix allografts, targeting applications such as spinal fusion, dental bone regeneration, sports medicine including ACL repair, breast reconstruction, wound repair, and joint surgeries. Products serve surgeons in dental clinics, orthopedic clinics, ambulatory surgical centers, hospitals, and aesthetic clinics worldwide, with operations centered in the United States and international markets. Founded in 1989 and headquartered in Belgrade, Montana, the company maintains laboratory and manufacturing facilities there, including ISO Class 1000 and ISO Class 100 clean rooms, along with offices in Phoenix, Arizona. In recent years, Lattice Biologics has pursued strategic shifts including a 2021 reorganization to emphasize psychedelics and cannabis markets via a new life sciences subsidiary combining psychedelic products with stem cell regenerative compounds; earlier developments encompassed room-temperature AmnioBoost for dental markets, reformulated DBM putty, DBM fiber plugs, and modified extracellular matrix for stem cell applications with provisional patents; and historical moves such as a reverse merger, debt-to-equity conversions, private placements, and a 2015 acquisition interest by Blackstone Ventures, though no major funding, acquisitions, or partnerships have been publicly reported since 2021.